CCCC C4 Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CCCC

Price (delayed)

$4.145

Market cap

$458.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.1

Enterprise value

$452.03M

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 89
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 34

C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment ...

Highlights
The quick ratio has surged by 60% year-on-year and by 15% since the previous quarter
The EPS has increased by 25% year-on-year and by 13% since the previous quarter
C4 Therapeutics's equity has increased by 20% YoY but it has decreased by 9% QoQ
CCCC's gross profit is down by 12% year-on-year and by 3% since the previous quarter
The company's revenue fell by 12% YoY and by 3% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.c4thera.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CCCC

CCCC stock price

How has the C4 Therapeutics stock price performed over time
Intraday
4.67%
1 week
13.25%
1 month
36.57%
1 year
169.16%
YTD
117.02%
QTD
57.6%

Financial performance

How have C4 Therapeutics's revenue and profit performed over time
Revenue
$34.86M
Gross profit
$34.86M
Operating income
-$113.84M
Net income
-$103.8M
Gross margin
100%
Net margin
-297.8%
The company's net margin fell by 15% YoY
CCCC's gross profit is down by 12% year-on-year and by 3% since the previous quarter
The company's revenue fell by 12% YoY and by 3% QoQ
The operating margin has contracted by 11% YoY

Price vs fundamentals

How does CCCC's price correlate with its fundamentals

Growth

What is C4 Therapeutics's growth rate over time

Valuation

What is C4 Therapeutics stock price valuation
P/E
N/A
P/B
1.73
P/S
14.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.97
The EPS has increased by 25% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 83% higher than the last 4 quarters average of 0.9 but 2.9% lower than the 5-year quarterly average of 1.7
C4 Therapeutics's equity has increased by 20% YoY but it has decreased by 9% QoQ
CCCC's price to sales (P/S) is 156% more than its last 4 quarters average of 5.6 but 8% less than its 5-year quarterly average of 15.5
The company's revenue fell by 12% YoY and by 3% QoQ

Efficiency

How efficient is C4 Therapeutics business performance
C4 Therapeutics's return on invested capital has decreased by 18% YoY
The return on sales has declined by 15% year-on-year
The company's return on assets fell by 14% YoY but it rose by 2.1% QoQ
C4 Therapeutics's ROE has decreased by 10% YoY but it has increased by 6% from the previous quarter

Dividends

What is CCCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CCCC.

Financial health

How did C4 Therapeutics financials performed over time
The quick ratio has surged by 60% year-on-year and by 15% since the previous quarter
The current ratio has soared by 58% YoY and by 15% QoQ
The company's debt is 75% lower than its equity
CCCC's debt to equity is down by 24% year-on-year but it is up by 9% since the previous quarter
C4 Therapeutics's equity has increased by 20% YoY but it has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.